BCL2L1 and cancer: While the small molecule inhibitor targeting BCL-2/BCL-xL/BCL-w (ABT-263) as a single agent has entered clinical experimentation in certain cancers, NSCLC is largely resistant to these inhibitors alone (Fig. S2A).